Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications-Reference-Cited by-同舟云学术

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications

Author:

Jain Nityanand¹²^ORCID,Umar Tungki Pratama³^ORCID,Fahner Anne-Fleur⁴⁵^ORCID,Gibietis Valdis⁶^ORCID

Affiliation:

1. Faculty of Medicine, Riga Stradinš University, Riga, Latvia

2. Joint Microbiology Laboratory, Pauls Stradinš Clinical University Hospital, Riga, Latvia

3. Faculty of Medicine, Sriwijaya University, Palembang, Indonesia

4. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA

5. Faculty of Biomedical Sciences, Vrije Universiteit, Amsterdam, Netherlands

6. Department of Internal Diseases, Riga Stradinš University, Riga, Latvia

Funder

external funding

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),Gastroenterology,Microbiology

Link

Reference48 articles.

3. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases;Vaishnavi C;Indian J Med Res,2010

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献